Back to top
more

Molina Healthcare (MOH)

(Delayed Data from NYSE)

$155.00 USD

155.00
1,622,290

+2.69 (1.77%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $154.88 -0.12 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 1% (243 out of 246)

Industry: Medical - HMOs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Molina Healthcare (MOH) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Molina Healthcare's (MOH) first-quarter results are likely to reflect the benefits of increased membership in the Medicare program.

Zacks Equity Research

Molina (MOH) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Molina (MOH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why Molina (MOH) is a Strong Growth Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Here's How Much You'd Have If You Invested $1000 in Molina a Decade Ago

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Zacks Equity Research

Should Vanguard S&P MidCap 400 ETF (IVOO) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IVOO

Zacks Equity Research

Molina Healthcare (MOH) Up 32% in a Year: Is More Upside Left?

by Zacks Equity Research

Continued revenue growth, well-performing Medicaid and Medicare businesses, expense saving initiatives and solid cash balance continue to drive Molina Healthcare (MOH).

Zacks Equity Research

Molina (MOH) Up 3.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Molina (MOH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Centene (CNC) Wins Contract to Serve Medicaid Members in Indiana

by Zacks Equity Research

Centene's (CNC) Indiana subsidiary receives a contract from the Indiana Department of Administration, thereby continuing to serve the unique health needs of Indiana communities.

Zacks Equity Research

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Should iShares Core S&P MidCap ETF (IJH) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IJH

Zacks Equity Research

Here's How Much You'd Have If You Invested $1000 in Molina a Decade Ago

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Zacks Equity Research

Should SPDR S&P MidCap 400 ETF (MDY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for MDY

Zacks Equity Research

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FXH

Zacks Equity Research

Molina (MOH) to Join S&P 500 Driven by Medicare Performance

by Zacks Equity Research

Molina Healthcare (MOH) is likely to leave S&P MidCap 400 and replace IHS Markit Ltd. in the S&P 500 Index.

Zacks Equity Research

Integra's (IART) Q4 Earnings Top Estimates, Gross Margin Drops

by Zacks Equity Research

Integra (IART) records strong recovery in order demand in Q4 on broad-based strength in Neurosurgery and sales from the company's new CereLink ICP monitoring.

Zacks Equity Research

Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y

by Zacks Equity Research

Fresenius Medical's (FMS) fourth-quarter earnings benefit from strong performance across all the geographic regions and segments.

Zacks Equity Research

Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Despite reporting a fourth-quarter loss, Glaukos' (GKOS) results reflect a noticeable rise in revenues.

Zacks Equity Research

Exact Sciences (EXAS) Q4 Revenues Top Estimates, Margin Down

by Zacks Equity Research

Exact Sciences' (EXAS) legacy Screening business saw strong momentum on solid Cologuard volume growth during the fourth quarter.

Zacks Equity Research

Tandem Diabetes (TNDM) Q4 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

Robust domestic and international pump shipments are driving Tandem Diabetes' (TNDM) fourth-quarter top line.

Zacks Equity Research

Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?

by Zacks Equity Research

Sector ETF report for FXH

Zacks Equity Research

Charles River (CRL) DSA Arm Sees Growth, Cell Supply Sluggish

by Zacks Equity Research

The acquisitions of Cognate BioServices and Vigene Biosciences contribute to the growth of Charles River's (CRL) Manufacturing Solutions arm.

Zacks Equity Research

Medtronic's (MDT) Q3 Earnings Beat, Revenues Lag Estimates

by Zacks Equity Research

Medtronic (MDT) registers organic growth in the Cardiovascular, Neuroscience and Diabetes segments in Q3.

Zacks Equity Research

Henry Schein (HSIC) Up 10.1% Since Posting Q4 Earnings Beat

by Zacks Equity Research

Henry Schein (HSIC) stock rallies on strong fourth-quarter performance and bullish 2022 EPS guidance.

Zacks Equity Research

Shockwave Medical (SWAV) Gains 3.2% Post Q4 Earnings Beat

by Zacks Equity Research

Shockwave Medical's (SWAV) fourth-quarter results reflect robust revenue growth and expansion in gross margin.

Zacks Equity Research

UnitedHealth Group (UNH) Bolsters Presence With Contract Win

by Zacks Equity Research

UnitedHealth Group's (UNH) unit UnitedHealthcare receives a contract from the District of Columbia aimed at improving health outcomes of District Dual Choice program enrollees in the district.